

Therapix Biosciences Spotlights in Financial and Trade Media Outlets

TEL AVIV, Israel, Nov. 21, 2017 [/PRNewswire/](#) --Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, has received positive media coverage in a variety of financial and trade media outlets.

A Q&A article featuring Adi Zulloff-Shani, Ph.D, Chief Technology Officer of Therapix, was published in *Drug Discovery and Development*. Titled "The 'Entourage Effect': How THC can team up with PEA to treat symptoms of Tourette syndrome," the article outlines the compounds involved in the Company's research and how they potentially work together, the status of the Company's Phase IIa clinical study for Tourette syndrome, how this treatment will be delivered and the Company's additional focus on a therapy for mild cognitive impairment. To read the Q&A, please visit: <https://www.dddmag.com/article/2017/11/entourage-effect-how-thc-can-team-pea-treat-symptoms-tourette-syndrome>.

An article published in *CFO Magazine*, titled "CFO Pushes Pharma Startup to Market," shares Therapix CFO Josh Blacher's insights on the opportunities facing the Company as it moves forward with its clinical studies in Tourette syndrome and sleep apnea and its preclinical data for mild cognitive impairment. To read the article, please visit: <http://ww2.cfo.com/growth-companies/2017/11/cfo-pushes-pharma-startup-to-market-cannabinoid/>.

In a podcast posted on *CFO Thought Leader*, titled "Garnering Investor Recognition: Josh Blacher, CFO, Therapix Biosciences," Mr. Blacher discusses the importance of the therapeutic areas Therapix is working in and the company's ongoing communications with stakeholders in the investment, medical and scientific communities while continuing its mission to one day provide an efficacious treatment to patients and their caregivers. To listen to the podcast, please visit: <http://www.cfothoughtleader.com/cfopodcasts/335-garnering-investor-recognition-josh-blacher-cfo-therapix-biosciences/>.

A brief published in *BioCentury* noted the company has named its Chairman, Dr. Ascher Shmulewitz, Ph.D, to the position of interim CEO. To read the brief, please visit <https://www.biocentury.com/bc-extra/company-news/2017-11-03/management-tracks-tissue-regenix-therapix?kwh=Therapix> (subscription required).

The articles and podcast at the links above are provided for informational purposes only. Therapix Biosciences is not responsible for the content of the linked articles and podcast.

About Therapix Biosciences:

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-110 and THX-120 for the treatment of Tourette syndrome (TS) and Obstructive Sleep Apnea (OSA); THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); and THX-150 for the treatment of infectious diseases. Please visit our website for more information at

www.therapixbio.com.

Forward-Looking Statements:

This press release contains forward-looking statements about the Company's expectations, beliefs, and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Such forward-looking statements used in this press release include, among other things, references to the clinical and commercial potential of THX-OSA01 for the treatment of Obstructive Sleep Apnea. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding needed to continue to pursue our business and product development plans, the inherent uncertainties associated with developing new products or technologies, our ability to obtain regulatory approval for our product candidates, our ability to commercialize our product candidates, competition in the industry in which we operate and overall market conditions. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Therapix Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is available on the SEC's website, www.sec.gov.

For further information:

Investor Contact:

Josh Blacher, CFO, Therapix Biosciences

+972-3-616-7055


josh@therapixbio.com

Media Contact:

Susan Forman, DGI

+1-212-825-3210

SOURCE Therapix Biosciences Ltd

Additional assets available online: 

<http://therapix.investorroom.com/2017-11-21-Therapix-Biosciences-Spotlighted-in-Financial-and-Trade-Media-Outlets>